Relmada Therapeutics (RLMD) Return on Capital Employed (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Return on Capital Employed data on file, last reported at 39.75% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 39.75%, up 21129.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 39.75% (up 21129.0% YoY), and the FY2025 annual result was 93.1%, up 4354.0% from the prior year.
• Return on Capital Employed improved to 39.75% in Q1 2026 per RLMD's latest filing, from 123.1% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 39.75% in Q1 2026 and troughed at 451.66% in Q3 2025.
• A 5-year average of 155.65% and a median of 113.76% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 28591 bps in 2025, then surged 21129 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 102.35% in 2022, then decreased by 11 bps to 113.76% in 2023, then tumbled by 82 bps to 207.24% in 2024, then surged by 41 bps to 123.1% in 2025, then surged by 68 bps to 39.75% in 2026.
• Business Quant data shows RLMD's Return on Capital Employed at 39.75% in Q1 2026, 123.1% in Q4 2025, and 451.66% in Q3 2025.